Key result
Reporting cardiac troponin concentrations between the detection limit and the 10% CV value as 'detectable' may maximize clinically useful information for identifying myocardial injury.
Answers are grounded in this paper and cite their sources.
This editorial proposes a reporting strategy for cardiac troponin assays that bridges analytical precision limits with clinical utility, emphasizing that any detectable troponin is clinically relevant.
There is currently substantial debate about how cardiac troponin concentrations should be reported. We would like to offer an alternative strategy to two recent recommendations. In a recent editorial, Apple and Wu (1) proposed that the concentration of cardiac troponin that corresponds to an analytical imprecision (CV) of 10% be used as a medical diagnostic guide. Panteghini et al. (2), in their document on quality specifications for cardiac troponin assays, state that “the detection limit … of cardiac troponin … should be significantly lower than the clinical discrimination limit used”. The main reason for this is that patient risk stratification based on results generated by assays not meeting this requirement would be compromised by considerable imprecision. In contrast, a recent article on the proposed new definition of myocardial infarction states that “A review of currently available data demonstrates no discernible threshold below which an increased value for cardiac troponin would be deemed harmless” (3). Thus, the first two views (1)(2) focus on ensuring that reported results are real, and the third (3) is intent on extracting the maximum clinically useful information. Is it possible to reconcile these imperatives? Current commercially available assays for cardiac troponin cannot detect the picomolar concentrations of protein that are reportedly present in the blood of healthy persons (4). This point is supported by recent work from Roche Diagnostics in their efforts to establish a reference value for cardiac troponin T. Among 1951 apparently healthy persons, only 19 had troponin T concentrations above the minimum detectable concentration of 0.010 μg/L (Roche Diagnostics, information on file). No information was available on the clinical outcome in the 19 apparently healthy individuals (0.014–0.039 μg/L). Regardless, the fact that >99% of this study group had undetectable cardiac troponin T concentrations argues strongly that the appropriate reference interval for cardiac troponin, at least with currently available commercial assays, is below the detection limit. In support of this, Pagani et al. (5) could find no measurable troponin I in 120 healthy persons. We would question the upper reference limit quoted for some troponin assays (Table 1). Reported characteristics of cardiac troponin I and T assay systems. cTnI, cardiac tropinin I; cTnT, cardiac troponin T; NA, data not available. Data derived from manufacturer’s package insert or obtained directly from manufacturing representatives. The mathematical model uses the between-run imprecision data determined at several troponin concentrations and substituted into the three-parameter variance function, ς2(U) = (β1 + β2U)J, where ς2(U) denotes variance and U denotes concentration, to calculate the parameters, β1, β2, and J. At the 99.9 percentile, i.e., the value at 3 SD above zero, the minimum detectable concentration was calculated after substitution of β1 and J into the variance equation at a concentration of U equal to zero (10). Data were obtained by local field laboratories from the daily repeat measurement of troponin using manufacturers’ controls and patient sera (Centaur) or heparin plasma (Dimension RxL and AxSYM) containing low concentrations of troponin (n = 7–49 runs; imprecision was determined at six or seven troponin concentrations). Data from Quinn-Hall et al. (12). Based on serum samples. Based on heparin- and EDTA-plasma samples (upper reference limits for different specimen types are not available for other assay systems). Reported characteristics of cardiac troponin I and T assay systems. cTnI, cardiac tropinin I; cTnT, cardiac troponin T; NA, data not available. Data derived from manufacturer’s package insert or obtained directly from manufacturing representatives. The mathematical model uses the between-run imprecision data determined at several troponin concentrations and substituted into the three-parameter variance function, ς2(U) = (β1 + β2U)J, where ς2(U) denotes variance and U denotes concentration, to calculate the parameters, β1, β2, and J. At the 99.9 percentile, i.e., the value at 3 SD above zero, the minimum detectable concentration was calculated after substitution of β1 and J into the variance equation at a concentration of U equal to zero (10). Data were obtained by local field laboratories from the daily repeat measurement of troponin using manufacturers’ controls and patient sera (Centaur) or heparin plasma (Dimension RxL and AxSYM) containing low concentrations of troponin (n = 7–49 runs; imprecision was determined at six or seven troponin concentrations). Data from Quinn-Hall et al. (12). Based on serum samples. Based on heparin- and EDTA-plasma samples (upper reference limits for different specimen types are not available for other assay systems). How then should cardiac troponin concentrations measured by currently available commercial assays be reported? If we accept the clinical observation that any troponin detectable is of pathologic significance, then the question becomes at what concentration is cardiac troponin detectable? To answer this question for each assay, we can determine the apparent troponin concentration of 10 or more replicates of a zero calibrator (within-run) and calculate the troponin concentration at 2 or 3 SD above the mean of these results. Above this value, any cardiac troponin present would be considered clinically significant. Between this value and the concentration that corresponds to a day-to-day CV of 10%, the concentration should be reported as “detectable”; above the 10% CV value, the actual quantity should be reported. We choose 10% because expert opinions from the National Academy of Clinical Biochemistry Committee (6) and the IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD) (2) recommend a CV of 10% at the clinical decision limit for troponin measurement. This is at variance with the increasingly common clinical practice of using the “functional sensitivity” (CV) of 20% as the practical cutpoint for reporting numerical values (7). The only concern with using a CV of 20% as the minimum requirement for a clinically relevant troponin value would be if it fell close to the detection limit. Reference to the data in Table 1 indicates that in all cases for which data were available, the 20% CV value is clearly above the detection limit. Although there is no evidence for the use of a CV of 20%, it has become established in clinical practice, at least for immunoassays. It would certainly be inappropriate to replace it with other criteria for which there is clearly opposing clinical evidence (8). In practice, manufacturers of commercial troponin assays determine the detection limit as the concentration corresponding to a signal 2 SD above the mean of replicate within-assay measurements of a zero calibrator (Table 1). Another way suggested by Panteghini et al. (2) is to calculate the troponin concentration that is approximately one-fifth of the analytically valid clinical decision limit, i.e., one-fifth of the troponin concentration with a CV of 10% (Table 1). Alternatively, the minimum detectable concentration can be derived from the imprecision data obtained at low troponin concentrations, including at least two troponin concentrations that cover the range between the detection limit and the clinical decision limit of the assay. Using the three-parameter variance function, ς2(U) = (β1 + β2U)J, where ς2(U) denotes variance, U denotes concentration, and β1, β2, and J are the parameters, the between-run imprecision data determined at six or seven troponin concentrations were used to calculate the parameters for an assay system. These were then substituted into the variance equation with U equal to zero to determine the minimum detectable concentration (9)(10). Using the Roche Diagnostics cardiac troponin T system as an example, the minimum detectable concentration at the 99.9 percentile, which corresponds to the troponin concentration with a signal 3 SD above zero, was 0.009 μg/L (Table 1). This concentration was near the quoted detection limit of 0.01 μg/L and close to the troponin concentration that was one-fifth the concentration at the clinical decision cutpoint, i.e., 0.007 μg/L. In six other widely used cardiac troponin I systems, the detection limit values agreed reasonably well when estimated by the three methods (Table 1). The mathematical model gives added confidence to the reporting of troponin as “detectable” when the signal lies between those corresponding to the detection limit and the troponin concentration at a CV of 10%. Precision data obtained from our own field laboratories and applied to the mathematical model give a real-life measure of the detectable concentration of troponin in current commercially available assays and highlight analytical and subsequent clinical differences that exist between these assays (Table 1). The reporting of any analyte depends on the use of some valid criteria for the boundary between detection and nondetection, taking into account the degree of assay imprecision that does not affect clinical interpretation. For cardiac troponin, if we use a decision point of 3 SD above the zero calibrator, we might falsely label ∼1 in 100 persons as having minor myocardial injury. Is there a greater potential for harm or good as a consequence? Two potential benefits arise. One is that the patient is given life-saving therapy, using the rationale that any troponin in the setting of coronary ischemia is associated with a worse prognosis. The other is the ability to accumulate data that enable us to test the hypothesis that any cardiac troponin associated with ischemia carries a worse prognosis. The potential downside is that patients may be started on therapy and experience an adverse reaction. The old definition of myocardial infarction used decision thresholds for myocardial markers. This definition was flawed in that despite stratifying persons into those with myocardial infarction and those without (unstable angina), the death rates were identical after 2 years (11). The prognostic importance of a very low concentration of cardiac troponin has recently been confirmed by Morrow et al. (8), who found that troponin concentrations that were detectable but below that corresponding to an analytical CV of 10% had adverse prognostic significance. Thus the clinical evidence is in disagreement with the proposal from Apple and Wu (1). The sole purpose of laboratory medicine is to provide clinically useful information. In this context, it appears that the clinically useful information is that any detectable cardiac troponin has pathologic significance. With the procedures we have outlined here, clinically significant low concentrations of cardiac troponin can now be defined with some confidence.
No takes yet. Share an insight, caveat, or question.
Tate et al. (2002) conducted an editorial in Myocardial injury. Reporting strategy for cardiac troponin was evaluated. Reporting cardiac troponin concentrations between the detection limit and the 10% CV value as 'detectable' may maximize clinically useful information for identifying myocardial injury.
Synapse has enriched 10 related papers. Consider them for comparative context: